Getting Involved with the W-ADRC — Investigational Treatment Studies

For More Information:

ICARA Study

The purpose of this study is to evaluate the safety and effectiveness
of an investigational drug, which may slow the progression in those with
mild to moderate Alzheimer’s Disease. Approximately 1150 subjects will
be randomized at approximately 200 study sites in the United States (US)
and Canada. All participants will remain on their current medications
and will receive 0.5 mg/kg, 1.0 mg/kg, or placebo. Participants will
receive, at no charge, the investigational drug and study related
physical exams, and laboratory services and tests. Throughout the study,
participants will be monitored by a medical team including a nurse or
study coordinator and a physician. If you are interested in this study,
please contact us.

 

GAP (Gammaglobulin Alzheimer’s Partnership) Study

This study is evaluating the safety and effectiveness of an investigational medication in slowing disease progression in adults diagnosed with mild to moderate Alzheimer’s disease. Qualified study participants and their study partner / caregiver will be asked to attend up to 48 office visits over 18 months. All study participants will be able to continue taking their current Alzheimer’s medications for the duration of the study. In addition to taking their current medications, participants will be randomly assigned to receive either:

  • Dose A of the study medication
  • Dose B of the study medication
  • Placebo 

Some of the study visits may be able to be done in the participant’s home.

To participate in this study, there are specific criteria that must be met.

  • Be between the ages of 50 and 89
  • Have mild to moderate Alzheimer’s disease
  • Have a caregiver who agrees to participate as a facilitator of your involvement and monitor status throughout the entire duration of the study, and complete questionnaires at select visits
  • Be able to have repeat infusions and blood draws
  • Not have other conditions that may affect participation in the study

Reimbursement may be provided.

For more information about the GAP (Gammaglobulin Alzheimer’s Partnership) Study please contact us.

 

Identity Study

This study is evaluating the safety and effectiveness of an investigational medication in slowing disease progression in adults diagnosed with mild to moderate Alzheimer's disease. Qualified study participants and their study partner / caregiver will be asked to attend up to 20 office visits over 22 months. All study participants will be able to continue taking their current Alzheimer's medications for the duration of the study. In addition to taking their current medications, participants will be randomly assigned to receive either:

  • Dose A of the study medication
  • Dose B of the study medication
  • Placebo

Sometime after week 64 of the study, all participants will receive study medication even if they were previously only taking a placebo. This delayed start will help researchers determine if LY450139 slows disease progression .

To participate in this study, there are specific criteria that must be met.

  • Be at least 55 years of age
  • Have mild to moderate Alzheimer's disease
  • Have a caregiver who spends at least 10 hours a week with the patient, and who can attend study visits, or be available on the telephone at arranged times
  • Be able to swallow tablets whole
  • Not have other conditions that may affect participation in the study

Reimbursement for travel-related expenses such as parking or public transportation may be provided.

If you are interested in this study, please contact us or download our brochure (requires free Adobe Acrobat Reader).

 

Combination Therapy Study for Veterans

The purpose of this study is to evaluate the potential benefit of combining several standard Alzheimer's disease treatments. Currently, patients may be prescribed either donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne), and may also be taking memantine (Namenda) and/or vitamin E. No study to date, however, has examined the effectiveness of combining these three treatments. Veterans (men and women) with a diagnosis of Alzheimer's disease who are taking Aricept, Exelon, or Razadyne, but not taking Namenda or vitamin E may be able to join this study and help us answer the questions about combination therapy. All participants will remain on their current medications and may receive either Namenda, or vitamin E, or both at no cost during the study. If you are interested in this study, please contact us or download our brochure (requires free Adobe Acrobat Reader).

 

RI Study

University of Wisconsin researchers are conducting a study on an experimental medication to block nerve damage and inflammation in the brain that can lead to progressive memory loss and behavioral changes in people with Alzheimer's disease. A protein called amyloid beta builds up in plaque deposits and may promote damage to nerve cells. The buildup of plaques can trigger inflammation in the brains of people with Alzheimer's disease. Researchers will test an experimental drug that seeks to stop amyloid beta from binding to a receptor in the brain called RAGE (receptor for advanced glycation endproducts). 400 volunteers with mild to moderate Alzheimer's disease are needed nationwide to further test this new approach. If you are interested in this study, please contact us or download our brochure (requires free Adobe Acrobat Reader)..